High MVD, measured as CD34 expression, has been shown to have significant prognostic value in different types of cancer: it is associated with poor survival in non-small-cell lung carcinoma (NSCLC) 48 and colorectal cancer 49, and with recurrence in bladder 50 and prostate 51 cancer. Here, CD34 is linked to non-small cell lung carcinoma.